This page uses content from Wikipedia and is licensed under CC BY-SA.

Rosonabant

Rosonabant
Rosonabant.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC21H21Cl3N4O
Molar mass451.777 g/mol g·mol−1
3D model (JSmol)

Rosonabant (INN; E-6776) is a drug acting as a CB1 receptor antagonist/inverse agonist that was under investigation by Esteve as an appetite suppressant for the treatment of obesity.[1][2] Development of the drug for clinical use was apparently halted shortly after the related CB1 antagonist rimonabant was discontinued,[when?] likely due to the reports of severe psychiatric adverse effects such as anxiety, depression, and suicidal ideation associated with it and with similarly-acting agents.[3][4][5]

See also

References

  1. ^ Janero DR, Makriyannis A (March 2009). "Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis". Expert Opinion on Emerging Drugs. 14 (1): 43–65. doi:10.1517/14728210902736568. PMID 19249987.
  2. ^ Tim C. Kirkham; S. J. Cooper (2007). Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. Academic Press. p. 325. ISBN 978-0-12-370633-1. Retrieved 12 May 2012.
  3. ^ Heal DJ, Gosden J, Smith SL (December 2009). "Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders". British Journal of Clinical Pharmacology. 68 (6): 861–74. doi:10.1111/j.1365-2125.2009.03549.x. PMC 2810797. PMID 20002080.
  4. ^ "Cannabidiol and Psychiatric Disorders". Retrieved 29 October 2019.
  5. ^ Lee HK, Choi EB, Pak CS (2009). "The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents". Current Topics in Medicinal Chemistry. 9 (6): 482–503. doi:10.2174/156802609788897844. PMID 19689362. Archived from the original on 2013-05-22.